More proof of what I am saying: nothing will move this stock back up as long as there is dilutive financing.
The second point is that this press release seems to have been written by someone with poor grammar and a very limited vocabulary.
I wonder if they read their own patents because it says that this patent, which is for the treatment of joint diseases like osteoarthritis, will be marketed under the brand WOUNDPULSE. How stupid can one be and still get a job at ENDV? No wonder it is down again. They cannot even write a press release and get it out properly. WOW!
News 
Market Data 
Discover 
